- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00263042
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes (CRESCENDO)
Randomized, Multinational, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.
The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV death, or CV hospitalization in these patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina
- Sanofi-Aventis Administrative Office
-
-
-
-
New South Wales
-
Macquarie Park, New South Wales, Australia
- sanofi-aventis Australia & New Zealand administrative office
-
-
-
-
-
Vienna, Austria
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Diegem, Belgium
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Sao Paulo, Brazil
- Sanofi-Aventis Administrative Office
-
-
-
-
Quebec
-
Laval, Quebec, Canada
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Santiago de Chile, Chile
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Shangaï, China
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Santafe de Bogota, Colombia
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Praha, Czech Republic
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Horsholm, Denmark
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Helsinki, Finland
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Paris, France
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Berlin, Germany
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Athens, Greece
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Hong-Kong, Hong Kong
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Budapest, Hungary
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Mumbai, India
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Dublin, Ireland
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Natanya, Israel
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Milano, Italy
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Seoul, Korea, Republic of
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Kuala Lumpur, Malaysia
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Mexico, Mexico
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Gouda, Netherlands
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Lysaker, Norway
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Lima, Peru
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Makati City, Philippines
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Warszawa, Poland
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Porto Salvo, Portugal
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Bucuresti, Romania
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Moscow, Russian Federation
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Singapore, Singapore
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Midrand, South Africa
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Madrid, Spain
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Bromma, Sweden
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Geneva, Switzerland
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Taipei, Taiwan
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Bangkok, Thailand
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Megrine, Tunisia
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Istanbul, Turkey
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Guildford, United Kingdom
- Sanofi-Aventis Administrative Office
-
-
-
-
New Jersey
-
Bridgewater, New Jersey, United States, 08807
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Waist circumference >102 cm (40 inches) males, >88 cm (35 inches) females, with one coronary heart disease (CHD) equivalent or two major risk factors for cardiovascular disease.
CHD equivalents:
- Recent (within 3 years)documented heart attack
- Documented symptomatic coronary artery disease
- Recent (within 3 years) ischemic cerebrovascular episode (stroke or TIA)
- Documented symptomatic peripheral arterial disease
Major risk factors:
- Documented type 2 diabetes mellitus
- Metabolic syndrome (NCEP criteria)
- Asymptomatic cerebrovascular, renal, or peripheral arterial disease, or past abdominal aortic aneurysm repair
- Elevated high-sensitivity C-reactive protein
- Age > or = 65 years for males, age > or = 70 years for females
Exclusion Criteria:
- Obesity of known endocrine origin
- Pregnant or breastfeeding women
- Very low calorie diet or weight loss surgery within past 6 months
- Presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation, including uncontrolled serious psychiatric illness
- Likely cardiovascular intervention within next 1 month
- Allergy to rimonabant or excipients, or prior participation in a rimonabant trial
- Receipt of investigational product within past 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo (for Rimonabant) once daily.
|
Tablet, oral administration
|
Experimental: Rimonabant
Rimonabant 20 mg once daily
|
Tablet, oral administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
First occurrence of any of myocardial infarction, stroke or cardiovascular (CV) death
Time Frame: From randomization up to common study end date (33-50 months)
|
From randomization up to common study end date (33-50 months)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
First occurrence of any of myocardial infarction, stroke, CV death, and CV hospitalization
Time Frame: From randomization up to common study end date (33-50 months)
|
From randomization up to common study end date (33-50 months)
|
All-cause mortality
Time Frame: From randomization up to common study end date (33-50 months)
|
From randomization up to common study end date (33-50 months)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Eric Topol, MD, Scripps Clinic
Publications and helpful links
General Publications
- Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X.
- Bhatia G, Bansal V, Harismendy O, Schork NJ, Topol EJ, Frazer K, Bafna V. A covering method for detecting genetic associations between rare variants and common phenotypes. PLoS Comput Biol. 2010 Oct 14;6(10):e1000954. doi: 10.1371/journal.pcbi.1000954.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EFC5826
- 2005-002942-20 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
-
Penn State UniversityAlmond Board of California; The Hershey CompanyCompletedCardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentCompleted
-
Aziyo Biologics, Inc.CompletedCardiovascular DiseaseUnited States
-
Monash UniversityCompletedCardiovascular DiseaseAustralia
Clinical Trials on Rimonabant
-
SanofiCompletedSmoking CessationFrance, Spain, Sweden, Switzerland, Belgium, Denmark, United Kingdom
-
SanofiCompletedSmoking CessationUnited States
-
SanofiTerminatedObesity | DyslipidemiasGermany, Netherlands, Turkey, Slovakia, United Kingdom, Finland, Hungary, Ireland, Italy, Norway, Greece, Sweden, Czech Republic, Portugal, Switzerland
-
SanofiCompletedType 2 Diabetes MellitusUnited States, Poland, Germany, Netherlands, Argentina, Hungary, Chile
-
SanofiCompletedMaintenance of Smoking CessationUnited States, Canada, Australia
-
SanofiCompletedSmoking CessationUnited States
-
SanofiTerminated
-
SanofiCompletedCoronary AtherosclerosisCanada, United States, Italy, Spain, Poland, Netherlands, Belgium, France, Australia
-
Weill Medical College of Cornell UniversityNational Institutes of Health (NIH); PWSAUSATerminatedPrader-willi SyndromeUnited States
-
SanofiTerminatedObesity | Weight LossRomania, Netherlands, Croatia, Finland, Hungary